Laura Solé

Laura Solé

Auto-generated profile, based on publicly available information

Laura Solé

Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LSLaura Solé
Laura Solé
TLTeresa Lobo-Jarne
Teresa Lobo-Jarne
DÁDaniel Álvarez-Villanueva
Daniel Álvarez-Villanueva
JAJosune Alonso-Marañón
Josune Alonso-Marañón
YGYolanda Guillén
Yolanda Guillén
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.

22 September 2023 in The EMBO Journal
Verified
Journal Article
Closed access
IPIrene Pecharromán
Irene Pecharromán
LSLaura Solé
Laura Solé
DÁDaniel Álvarez‐Villanueva
Daniel Álvarez‐Villanueva
TLTeresa Lobo‐Jarne
Teresa Lobo‐Jarne
JAJosune Alonso‐Marañón
Josune Alonso‐Marañón
Lluis EspinosaLluis Espinosa
Lluis Espinosa

30 July 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EBEster Bonfill-Teixidor
Ester Bonfill-Teixidor
ANAlmudena Neva-Alejo
Almudena Neva-Alejo
AAAlexandra Arias
Alexandra Arias
ICIsabel Cuartas
Isabel Cuartas
RIRaffaella Iurlaro
Raffaella Iurlaro
JSJoan Seoane
Joan Seoane
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.

11 March 2025 in Science Signaling
Verified
Journal Article
Closed access
JAJosune Alonso-Marañón
Josune Alonso-Marañón
LSLaura Solé
Laura Solé
DÁDaniel Álvarez-Villanueva
Daniel Álvarez-Villanueva
MMMaria Maqueda
Maria Maqueda
TLTeresa Lobo-Jarne
Teresa Lobo-Jarne
Lluis EspinosaLluis Espinosa
Lluis Espinosa
The DNA damage repair kinase ATM is phosphorylated by the NF-κB pathway kinase IKKα, resulting in enhanced DNA damage repair through the nonhomologous end-joining pathway. Thus, inhibition of IKKα enhances the efficacy of cancer therapy based on inducing DNA damage. Here, we found a role for the IKK regulatory subunit NEMO in DNA damage repair mediated by ATM and IKKα. Exposure to damaging agents induced the interaction of NEMO with a preformed ATM-IKKα complex, which was required to target active ATM and IKKα to chromatin for efficient DNA damage repair but not for activating ATM. Recognition of damaged DNA by the IKKα-NEMO-ATM complex was facilitated by the interaction between NEMO and histones and depended on the ADP ribosylation of histones by the enzyme PARP1. NEMO-deficient cells showed increased activity of the kinase ATR, and inhibition of ATR potentiated the effect of chemotherapy in cells lacking NEMO or IKKα. Bioinformatic analysis of colorectal cancer datasets demonstrated that the expression of genes encoding IKKα, NEMO, and ATM correlated with poor patient prognosis, suggesting that the mechanism linking these three elements may be clinically relevant.

3 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADaniel Alvarez-Villanueva
Daniel Alvarez-Villanueva
MMMaría Maqueda
María Maqueda
DHDina Harti
Dina Harti
ECEric Canton
Eric Canton
EAEvelyn Andrades
Evelyn Andrades
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Colorectal cancer (CRC) frequently develops aggressive metastatic disease, yet the cellular features that enable dissemination remain poorly defined. IKKα, a kinase traditionally linked to stress and inflammatory signaling, is increasingly recognized for broader functions in cancer. Here, we show that loss of IKKα unexpectedly promotes metastasis in CRC. Using patient-derived organoids, we find that genetic or pharmacological inhibition of IKKα stabilizes tight-junction components, leading to the emergence of compact epithelial clusters with a heightened ability to spread and colonize the liver. Single-cell transcriptomics reveals expansion of a CDH17⁺/CLDN2⁺ epithelial subpopulation that dominates metastatic lesions, a finding validated by tissue staining. Remarkably, disrupting CLDN2 completely eliminates the metastatic advantage caused by IKKα loss. These results identify a metastasis-competent epithelial state driven by tight-junction remodeling and uncover a vulnerable node that may be exploited therapeutically in aggressive colorectal cancer.

8 June 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
FGFernando Gallardo
Fernando Gallardo
EAEvelyn Andrades
Evelyn Andrades
AIArnau Iglesias
Arnau Iglesias
JGJessica González
Jessica González
LSLaura Solé
Laura Solé
Lluis EspinosaLluis Espinosa
Lluis Espinosa
Current therapeutic approaches for Sézary syndrome (SS) do not achieve a significant improvement in long-term survival of patients, and they are mainly focused on reducing blood tumor burden to improve quality of life. Eradication of SS is hindered by its genetic and molecular heterogeneity. Determining effective and personalized treatments for SS is urgently needed. The present work compiles the current methods for SS patient–derived xenograft (PDX) generation and management to provide new perspectives on treatment for patients with SS. Mononuclear cells were recovered by Ficoll gradient separation from fresh peripheral blood of patients with SS (N = 11). A selected panel of 26 compounds that are inhibitors of the main signaling pathways driving SS pathogenesis, including NF-kB, MAPK, histone deacetylase, mammalian target of rapamycin, or JAK/STAT, was used for in vitro drug sensitivity testing. SS cell viability was evaluated by using the CellTiter-Glo_3D Cell Viability Assay and flow cytometry analysis. We validated one positive hit using SS patient–derived Sézary cells xenotransplanted (PDX) into NOD-SCID-γ mice. In vitro data indicated that primary malignant SS cells all display different sensitivities against specific pathway inhibitors. In vivo validation using SS PDX mostly reproduced the responses to the histone deacetylase inhibitor panobinostat that were observed in vitro. Our investigations revealed the possibility of using high-throughput in vitro testing followed by PDX in vivo validation for selective targeting of SS tumor cells in a patient-specific manner.